TICKERNERD
Menu
ATYRATYRHealthcare · Biotechnology

ATYR Stock Forecast: aTyr Pharma, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.50
+0.28% on the day

The 9 Wall Street analysts covering aTyr Pharma, Inc. hold a median 12-month price target of $3 — +494.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$49.5M
Ticker Nerd rank
51 / 100
Median analyst target
$3.00
Analysts covering
9
Total return, dividends reinvested
1W
−9.8%
1M
+3.8%
YTD
−35.6%
1Y
−89.8%
From 52W high
−91.6%
From 52W low
+27.4%
$0.40
$6.03
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATYR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores aTyr Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
82
Growth
80
Accruals
77
Revisions
69
Issuance
59
Volatility
42
Quality
28
Value
16
Momentum
4

Size (82): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATYR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATYR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26ATYRHigh $7.00Median $3.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
4 Buy5 Hold0 Sell
Low $1.00Median $3.00High $7.00

The green dot is the last close — the median target sits +494.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 May 2026Freedom BrokerUpgradeBuy$1.00 → $3.50
7 Nov 2025RBC CapitalMaintainsSector Perform—
16 Sept 2025RBC CapitalDowngradeSector Perform—
16 Sept 2025Wells FargoDowngradeEqual-Weight—
15 Sept 2025Cantor FitzgeraldDowngradeNeutral—
15 Sept 2025HC Wainwright & Co.DowngradeNeutral—
15 Sept 2025Jones TradingDowngradeHold—
15 Sept 2025Leerink PartnersDowngradeMarket Perform—
15 Sept 2025LUCID CAPITAL MARKETSDowngradeNeutral—
22 Aug 2025JefferiesMaintainsBuy—
20 June 2025Wells FargoMaintainsOverweight—
4 June 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
14 Mar 2025HC Wainwright & Co.ReiteratesBuy—
18 Feb 2025Leerink PartnersInitiatesOutperform—
6 Jan 2025Cantor FitzgeraldInitiatesOverweight—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
3 Dec 2024HC Wainwright & Co.ReiteratesBuy—
29 Oct 2024HC Wainwright & Co.ReiteratesBuy—
4 Oct 2024Wells FargoInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATYR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ATYR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

aTyr Pharma, Inc. (ATYR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 81% of US stocks

Price / sales
258.9×

Cheaper than 3% of US stocks

Price / book
1.0×

Cheaper than 73% of US stocks

EV / EBITDA
−0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−33609.5%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−98.7%

Higher than 13% of US stocks

Return on assets
−46.6%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ATYR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATYRaTyr Pharma, Inc.$49.5M
51
RNAZTransCode Therapeutics, Inc.$48.6M
23
HYPDHyperion DeFi, Inc.$48.2M
30
IBOImpact BioMedical, Inc.$50.2M
24
TCRXTScan Therapeutics, Inc.$50.9M
37
TILInstil Bio, Inc.$51.4M
50
FLNAFilana Therapeutics, Inc.$46.4M
58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own aTyr Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATYR news & analysis

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

GlobeNewsWire · 7 Aug 2026neutral

aTyr Pharma announced its second quarter 2026 results along with a program prioritization and corporate restructuring that includes a workforce reduction of approximately 60% to conserve capital and focus resources on its efzofitimod program in interstitial lung disease (ILD). The company is awaiting FDA comments by the end of August 2026 on a protocol submitted for a planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Why it matters — ATYR watchers would care because the company is concentrating its resources on the efzofitimod ILD program and awaiting FDA feedback on the planned Phase 3 sarcoidosis study, which represents a key next step for the pipeline.

FAQ

Frequently asked questions about ATYR stock

What is the ATYR stock price forecast for 2026-2027?

The 9 Wall Street analysts covering aTyr Pharma, Inc. have a median 12-month price target of $3, with estimates ranging from $1 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATYR stock a buy right now?

Of the 9 analysts covering aTyr Pharma, Inc., 4 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks aTyr Pharma, Inc. 51 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATYR?

As at 22 Aug 2026, aTyr Pharma, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).

Will ATYR stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +494.8% from the last close, and Ticker Nerd's factor model ranks aTyr Pharma, Inc. 51 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATYR stock forecast for 2030?

No analyst covering aTyr Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATYR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $7 over the next 12 months.

How has ATYR stock performed over the past year?

aTyr Pharma, Inc. returned -89.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does aTyr Pharma, Inc. do?

Atyr Pharma Inc. is a clinical-stage biotechnology company focused on discovering and developing first-in-class medicines derived from its proprietary tRNA synthetase platform.

What is the latest news on ATYR?

The most recent item we track (GlobeNewsWire, 7 Aug 2026): "aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD". aTyr Pharma announced its second quarter 2026 results along with a program prioritization and corporate restructuring that includes a workforce reduction of approximately 60% to conserve capital and focus resources on its efzofitimod program in interstitial lung disease (ILD). The company is awaiting FDA comments by the end of August 2026 on a protocol submitted for a planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Company

About aTyr Pharma, Inc.

Atyr Pharma Inc. is a clinical-stage biotechnology company focused on discovering and developing first-in-class medicines derived from its proprietary tRNA synthetase platform. The company translates tRNA synthetase biology into therapies targeting fibrosis and inflammation, addressing unmet needs in rare immune-mediated disorders. Its lead product candidate, efzofitimod, is a selective modulator of neuropilin-2 (NRP2) currently in Phase 3 clinical trials for pulmonary sarcoidosis and Phase 2 trials for systemic sclerosis-related interstitial lung disease and other interstitial lung diseases, including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD. Atyr Pharma Inc. also advances earlier-stage candidates like ATYR0101, a fusion protein from aspartyl-tRNA synthetase for fibrosis, and ATYR0750, a domain of alanyl-tRNA synthetase for liver disorders. Operating in the biopharmaceutical sector, the company emphasizes innovative immunomodulatory approaches to downregulate immune responses in fibrotic conditions. Founded in 2005 and headquartered in San Diego, California, Atyr Pharma Inc. plays a role in advancing treatments for severe pulmonary and inflammatory diseases.

CEO Dr. Sanjay S. Shukla M.D., M.S. · 58 employees · United States · https://atyrpharma.com